A phase I/II study of triple-mutated oncolytic herpes virus G47∆ in patients with progressive glioblastoma

Tomoki Todo; Yasushi Ino; Hiroshi Ohtsu; Junji Shibahara; Minoru Tanaka

doi:10.1038/s41467-022-31262-y

Nature Communications (Jul 2022)

A phase I/II study of triple-mutated oncolytic herpes virus G47∆ in patients with progressive glioblastoma

Tomoki Todo,
Yasushi Ino,
Hiroshi Ohtsu,
Junji Shibahara,
Minoru Tanaka

Affiliations

Tomoki Todo: Division of Innovative Cancer Therapy, Advanced Clinical Research Center, and Department of Surgical Neuro-Oncology, The Institute of Medical Science, The University of Tokyo
Yasushi Ino: Division of Innovative Cancer Therapy, Advanced Clinical Research Center, and Department of Surgical Neuro-Oncology, The Institute of Medical Science, The University of Tokyo
Hiroshi Ohtsu: Department of Data Science, National Center for Global Health and Medicine in Japan
Junji Shibahara: Department of Pathology, Kyorin University School of Medicine
Minoru Tanaka: Division of Innovative Cancer Therapy, Advanced Clinical Research Center, and Department of Surgical Neuro-Oncology, The Institute of Medical Science, The University of Tokyo

DOI: https://doi.org/10.1038/s41467-022-31262-y
Journal volume & issue: Vol. 13, no. 1
pp. 1 – 13

Abstract

Read online

G47Δ is a third-generation, triple-mutated oncolytic HSV-1 that has demonstrated anti-tumor efficacy in preclinical studies. Here the authors report the results of a phase I/II study of G47Δ in patients with recurrent or progressive glioblastoma.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal